(Q34971081)

English

Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

0 references

Edward A. Stadtmauer

3

object named as

Edward A Stadtmauer

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

Ivana N Micallef

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Patrick J Stiff

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Brian J Bolwell

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Auayporn P Nademanee

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Richard T Maziarz

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Angela M Partisano

7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sachin Marulkar

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

John F DiPersio

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

publication date

9 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

88

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1017-1023

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295654

8 July 2018

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295654

8 July 2018

Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295654

8 July 2018

Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295654

8 July 2018

A gerontologic perspective on cancer and aging

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295654

8 July 2018

Mobilizing the older patient with myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295654

8 July 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295654

8 July 2018

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23561

21 January 2018

Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23561

21 January 2018

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23561

21 January 2018

AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23561

21 January 2018

Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23561

21 January 2018

Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23561

21 January 2018

Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23561

21 January 2018

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295654

26 October 2018

The VAD chemotherapy regimen plus a G-CSF dose of 10 μg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 μg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23561

21 January 2018

Blood stem cell collections in multiple myeloma: definition of a scoring system

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23561

21 January 2018

Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23907769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23907769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/23907769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23907769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stem cell mobilization in multiple myeloma patients: do we need an age-adjusted regimen for the elderly?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23907769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23907769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23907769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peripheral blood stem cell collection in elderly patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23907769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23907769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/AJH.23561

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34971081&oldid=1604165608"